Advertisement

Organisation › Details
Syncona (Group)
Syncona’s purpose is to invest to extend and enhance human life. We do this by founding and building a portfolio of global leaders in life science to deliver transformational treatments to patients in areas of high unmet need. Our strategy is to found, build and fund companies around exceptional science to create a diversified portfolio of 15-20 globally leading healthcare businesses for the benefit of all our stakeholders. We focus on developing treatments for patients by working in close partnership with world-class academic founders and management teams. Our balance sheet underpins our strategy enabling us to take a long-term view as we look to improve the lives of patients with no or poor treatment options, build sustainable life science companies and deliver strong risk-adjusted returns to shareholders. *
![]() |
Start | 2018-11-21 existent |
![]() |
Industry | venture capital |
Industry 2 | LIFE SCIENCES | |
![]() |
Person | Murphy, Martin (Syncona CEO before Wellcome Trust Sigma project + MVM Life Science Partners + 3i + McKinsey) |
Person 2 | Jonikas, Magdalena A. (Wellcome Trust 201811 Partner at Syncona Investment Management Ltd) | |
![]() |
Region | Guernsey |
Country | United Kingdom (GB) | |
Street | St Julian’s Avenue, St Peter Port Arnold House, PO Box 273 | |
City | GY1 3RD Guernsey, Channel Islands | |
Address record changed: 2024-01-05 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: Clade Therapeutics Inc.. (11/3/21). "Press Release: Clade Therapeutics Raises $87 Million Series A Financing to Realize the Potential of Cell Therapy". Cambridge, MA. | ||
Record changed: 2023-04-05 |
Advertisement

More documents for Syncona (Group)
- [1] iOnctura B.V.. (6/20/24). "Press Release: iOnctura Announces EUR80 Million Series B Financing to Progress Pipeline through Phase II Trials". Geneva & Amsterdam....
- [2] Freeline Therapeutics Holdings plc. (11/22/23). "Press Release: Syncona to Acquire Freeline Therapeutics". London....
- [3] Beacon Therapeutics Holdings Ltd.. (6/12/23). "Press Release: Beacon Therapeutics Launches with £96 Million ($120 Million) to Develop a New Generation of Gene Therapies for Retinal Diseases Resulting in Blindness". London & Oxford....
- [4] Syncona Ltd.. (4/5/23). "Press Release: Syncona Appoints Roel Bulthuis as Managing Partner"....
- [5] SwanBio Therapeutics, Inc.. (5/18/22). "Press Release: SwanBio Therapeutics Announces $56 Million Series B Financing to Advance Novel Gene Therapies for Neurological Conditions". Philadeliphia, PA....
- [6] Clade Therapeutics Inc.. (11/3/21). "Press Release: Clade Therapeutics Raises $87 Million Series A Financing to Realize the Potential of Cell Therapy". Cambridge, MA....
- [7] Purespring Therapeutics Ltd.. (7/30/21). "Press Release: Syncona Founds Purespring with a £45m Series A Financing"....
- [8] Quell Therapeutics Ltd.. (2/11/21). "Press Release: Quell Therapeutics Expands Series A Financing to $84 Million". London....
- [9] Syncona Ltd.. (12/2/20). "Press Release: Resolution Therapeutics Announces a £26.6m Series A Financing from Syncona Ltd"....
- [10] Achilles Therapeutics Ltd.. (12/1/20). "Press Release: Achilles Therapeutics Appoints Robert Coutts as Chief Financial Officer". Stevenage....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top